Keyphrases
Complement Activation
100%
Complement System
100%
Endothelin-1 (ET-1)
100%
Normal Pregnancy
100%
Endothelin System
100%
Placental Ischemia
100%
Hypertension
85%
Placenta
85%
Endothelin Receptor
57%
Atrasentan
42%
Fetal Growth Restriction
28%
Complement Receptors
28%
New-onset Hypertension
28%
Fetal Weight
28%
Reduced Uterine Perfusion Pressure
28%
Kidney
14%
Hypertensive Disorders of Pregnancy
14%
Innate Immune Response
14%
Rat Model
14%
Blood Flow
14%
Fetal Growth
14%
Preeclampsia
14%
Pregnancy Outcome
14%
Local Complementation
14%
Immune Complement
14%
Uterus
14%
Mechanical Obstruction
14%
C3 Deposition
14%
Complement System Activation
14%
Inhibiting Effect
14%
Pregnant Rats
14%
Receptor Antagonism
14%
CD55
14%
Complex Interplay
14%
Endothelin Receptor Antagonist
14%
Pressure Model
14%
Activation Products
14%
Plasma Endothelin
14%
Endothelin B Receptor
14%
Complement Regulators
14%
Crry
14%
Independent Pathway
14%
Endothelin Pathway
14%
Medicine and Dentistry
Ischemia
100%
Complement System
100%
Endothelin System
100%
Endothelin
100%
Complement Activation
77%
Placenta
66%
Endothelin A Receptor
44%
Complement Component C3a
44%
Fetus Growth
33%
Atrasentan
33%
Preproendothelin
33%
Fetus Weight
22%
Complement Component C3b Receptor
22%
Blood Flow
11%
Pre-Eclampsia
11%
Gestational Hypertension
11%
Obstruction
11%
Endothelin A Receptor Antagonist
11%
Decay Accelerating Factor
11%
Endothelin B Receptor
11%
Complement Regulator
11%
Pharmacology, Toxicology and Pharmaceutical Science
Ischemia
100%
Endothelin
100%
Complement Component C3a
36%
Endothelin A Receptor
36%
Atrasentan
27%
Preproendothelin
27%
Complement Component C3b Receptor
18%
Rat Model
9%
Maternal Hypertension
9%
Obstruction
9%
Preeclampsia
9%
Endothelin A Receptor Antagonist
9%
Endothelin B Receptor
9%
Decay Accelerating Factor
9%
Biochemistry, Genetics and Molecular Biology
Endothelin
100%
Complement Activation
41%
Eicosanoid Receptor
29%
Fetus Growth
17%
Complement System
11%
Perfusion Pressure
11%
Fetus Weight
11%
Complement Receptor 1
11%
Rat Model
5%
Independent Pathway
5%
Blood Flow
5%
Receptor Antagonist
5%
Decay-Accelerating Factor
5%